ET Reddit Mentions | ChartExchange

Alright regards. From the guy who brought you [LASE](https://www.reddit.com/r/pennystocks/comments/1tutlnv/lase_a_real_sleeper_on_the_verge_of_contract_with/) last time, 3x the money when i post and gots hundreds of thank you. Now i bring you another sleeper.
Invivyd $IVVD is a fun one. It's a small biotech company with real revenue, a product on a regulatory timer, and a Phase 3 readout that could land any day now. There's an independent paper on VYD2311, a closer look at the short side, and a sharp Stocktwits read on timing. If you are burned by many craps pennystock that got posted here, pay attention to this one.
**Where things stand**
The stock was around $0.90 on Thursday, down from $1.02 earlier in the week, which puts the market cap at roughly $260M by my math.
Invivyd ended Q2 with $160.1 million in cash, which management expects to carry it through the DECLARATION readout and launch prep. Burn runs near $40M a quarter, so figure roughly $120M today and about three quarters of runway.
The big structural issue: PEMGARDA's emergency use authorization now ends June 29, 2027. That's essentially all of Invivyd's current revenue. So what you're really buying is an option on VYD2311 replacing it.
**The trial**
DECLARATION is randomized, triple-blind and placebo-controlled, testing single or monthly intramuscular doses against placebo, with prevention of symptomatic COVID at 3 months as the primary endpoint. It was upsized by about 500 subjects to strengthen statistical power.
Safety has looked clean so far. After reviewing unblinded safety data, the independent monitoring committee recommended cutting post-dose monitoring from two hours to 30 minutes.
There's a second readout in the wings too. LIBERTY, roughly 210 participants comparing VYD2311 with an mRNA vaccine, may report alongside DECLARATION.
**The September 1 twist**
When Chairman Marc Elia became CEO on September 1, the company also laid out two paths for topline. It can fully unblind and file for traditional approval. Or it can partially unblind, keeping clinical events blinded, and file for Accelerated Approval based on antiviral activity and safety, with a confirmatory cohort afterward.
That's a smart fallback if the trial comes up short on statistical power. It also tells you management sees that risk as real. If the headline says "partially unblinded," expect the market to treat it like a miss, whatever the rest of the release says.
**The new JCI Insight paper**
This one is genuinely good news. It comes from David Ho's lab at Columbia, and none of the authors hold equity in, receive payments from, or consult for Invivyd.
The findings are strong. VYD2311 was roughly 27 to 124 times more potent than pemivibart against JN.1, XFG, BA.3.2.2 and NB.1.8.1, covering today's dominant variants and the very different newcomer BA.3.2.2. The dosing math works too. Phase 1/2 doses kept serum levels above 10 μg/mL at 90 days, while the toughest variant, NB.1.8.1, needed only about 1.05 μg/mL for 90% neutralization. That's roughly a 10x cushion.
The caveats are real though. The lab tested research-grade antibody it made itself, in pseudovirus assays, and the PK conclusion depends on confirmation that VYD2311 behaves like its parent molecule. Blood levels also aren't the same as protection in the nose, where infection starts. And the paper says nothing about whether DECLARATION racked up enough COVID cases to prove anything, which remains the main risk. It's also not fresh: it first appeared as an in-press preview on August 11.
Where it really helps is Plan B. An independent, peer-reviewed potency case is exactly what an Accelerated Approval filing on antiviral activity would lean on. One twist: the same paper raises concerns about PEMGARDA's continued efficacy against newer variants. Great for the VYD2311 story, less great for today's revenue.
**Probability and rerating**
With the paper in hand, I'd put a clean, statistically significant win at roughly 50–60%, and some viable BLA path at about 80%. Mapping outcomes from \~$0.90, with prices adjusted for the raise that follows almost any result:
|**Outcome**|**My odds**|**Price range**|**vs \~$0.90**|
|:-|:-|:-|:-|
||
|Clean win, full unblind|\~50%|$2.50–4.00|\+178% to +344%|
|Partial unblind, Accelerated Approval route|\~30%|$0.55–0.90|−39% to flat|
|Messy, ambiguous data|\~12%|$0.40–0.60|−56% to −33%|
|Clear miss|\~8%|$0.20–0.35|−78% to −61%|
Weighted, that lands comfortably above $0.90 on my numbers. But three of the four rows are flat or down, and everything hangs on that top probability, which nobody outside the company actually knows. One row pays; the rest cost.
**Short squeeze potential**
The short data tells a pretty clear story: there's real fuel here, but nobody's feeling the heat yet.
The fuel; About 14.33% of the float is sold short, roughly 29.8M shares. That's meaningful, though still below the 20–30% zone where the famous squeezes usually start. It also implies a float of around 208M shares, so this isn't a tiny-float rocket like TOPS or FBGL.
The standout number is days to cover at 16.19. At normal volume, shorts would need more than three weeks to get out, so a sudden volume spike on good news could send a lot of them for the exit at once.
**The pressure, and this is where the setup falls short.** The borrow fee is only 0.41–0.55%, so staying short costs almost nothing. Genuine squeeze setups tend to show fees in the double or even triple digits.
Borrow availability is also rising, from 5.9M to 6.5M shares, so there's plenty of stock for new shorts to reload into any spike. In a real squeeze, that number drains toward zero.
The 55–75% off-exchange short volume looks dramatic, but it's mostly market makers shorting to fill buy orders and closing quickly. I'd treat it as noise.
The company's side. Invivyd has a live ATM, and an offering is likely (may or may not) right after good data. That hands shorts even more shares to cover into.
On a clean DECLARATION win, covering from that high days-to-cover should add real fuel to the opening pop. Without tight borrow, though, expect the move to fade as new shorts and fresh supply step in, rather than a multi-day squeeze. On anything less than a clean win, the shorts get paid.
**When does the data drop?**
Stocktwits user [ItsOkImANurse](https://stocktwits.com/ItsOkImANurse/message/665014156) put together a really useful read on timing (quoted as posted, minus the Stocktwits ticker card):
"for biotech topline clinical data, Monday through Thursday is the normal zone, and Tuesday–Thursday tends to feel especially common. Friday releases happen, but companies generally avoid dropping major market-moving data late Friday unless timing dictates it.
For IVVD specifically, their history is actually pretty useful:
·       Monday: Dec. 18, 2023 — positive CANOPY Phase 3 results; Feb. 3, 2025 — positive VYD2311 Phase 1/2 data.
·       Tuesday: Nov. 12, 2024 — CANOPY clinical data/preprints; May 27, 2025 — CANOPY publication/data; Feb. 24, 2026 — new clinical analysis.
·       Thursday: June 26, 2025 — full VYD2311 Phase 1/2 clinical data, released at 7:01 AM ET.
·       Friday: March 22, 2024 — interim CANOPY exploratory data, so they clearly will use Friday when necessary.
Release?
Tomorrow Friday: possible, but not my favorite
Monday Sept. 28: very plausible
Tuesday Sept. 29: probably my favorite
Wednesday Sept. 30: extremely plausible because it’s literally the final day of Q3
Solid logic, and it lines up with the company's own plan. Management said it will host an investor call once the study wraps instead of doing a Q2 earnings call, so expect a premarket release with a call attached. His 7:01 AM ET example works out to 11:01 UTC. He posted on Thursday, so his "tomorrow Friday" is today.
If September 30 passes with nothing, that's information too. Slipping past "late Q3" would make the market nervous, especially with a two-path decision in play"
**Last word**
IVVD is a true sleeper gem in this biotech space. Granted biotech is hit and miss but when it hit it hit hard. And I believe IVVD is one of them. BTIG and Cantor rate them as buy with target at $10. Institutional holder is at 90% more.
Shoutout to [u/justinrosser](/user/justinrosser/) who introduced me to this stock.
May God (or whatever deity you believe in or not) help us all.
Lets goooo

.dark-mode .CxF524{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .CxF524{ color: #333333; background-color: white; border: 2px solid #333333; }ETEnergy Transfer LP Common Units representing limited partner interestsstock NYSE

ET
Energy Transfer LP Common Units representing limited partner interests
stock NYSE